15 Frequently Asked Questions: Leukemia, Lymphoma and Blood Cancer Treatments in India for Kenyan Patients

Author:- Dr. Dheeraj Bojwani Date Created:- 12-09-2026

Introduction

Leukemia, lymphoma and other blood cancers require specialised diagnosis and treatment because they involve the blood, bone marrow, lymphatic system or immune system. Unlike many solid tumours, treatment is often based on the exact blood-cancer subtype, genetic and molecular findings, disease risk, previous treatment and the patient's overall condition. Treatment may include chemotherapy, targeted therapy, immunotherapy, radiation therapy, stem-cell or bone-marrow transplantation and, for selected patients, advanced cellular therapies such as CAR-T-cell therapy. Kenyan patients may consider India for specialist hematology and hemato-oncology evaluation, second opinions, advanced diagnostic testing, complex chemotherapy, targeted treatments, stem-cell transplantation and selected cellular therapies. Indian specialised centres provide chemotherapy for adult and paediatric hematological cancers, hematopoietic stem-cell transplantation and cellular/CAR-T therapy for selected cancers.

Healing Journeys of Kenyan Patients

Kenyan Patients Share Their Experience

In Brief

Leukemia, lymphoma and other blood cancers require specialised diagnosis and treatment because they involve the blood, bone marrow, lymphatic system or immune system. Unlike many solid tumours, treatment is often based on the exact blood-cancer subtype, genetic and molecular findings, disease risk, previous treatment and the patient's overall condition. Treatment may include chemotherapy, targeted therapy, immunotherapy, radiation therapy, stem-cell or bone-marrow transplantation and, for selected patients, advanced cellular therapies such as CAR-T-cell therapy.

Q1 · Why Do Kenyan Patients Consider Leukemia, Lymphoma and Blood Cancer Treatment in India?

Kenyan patients may consider India when they require specialised hematology assessment or a complex blood-cancer treatment plan.

Potential reasons include

• Detailed hematology and hemato-oncology evaluation
• Second opinions for difficult or unclear diagnoses
• Bone-marrow examination and pathology review
• Flow cytometry and immunophenotyping
• Cytogenetic and molecular testing
• Chemotherapy
• Targeted therapy
• Immunotherapy
• Radiation therapy for selected blood cancers
• Stem-cell/bone-marrow transplantation
• Autologous and allogeneic transplantation
• Haploidentical transplantation for selected patients
• Cellular therapy and CAR-T therapy at specialised centres
• Treatment of relapsed or refractory disease
• Adult and paediatric blood-cancer care
• Supportive and palliative treatment

The treatment should not be selected simply because a particular technology is available. The exact leukemia, lymphoma or other blood cancer must first be confirmed and classified.

India has specialised centres providing hematological cancer chemotherapy, stem-cell transplantation and cellular/CAR-T therapy for selected adult and paediatric cancers.

Kenya also has a growing oncology system. Therefore, the decision to travel should be based on the patient's specific diagnosis and required treatment rather than assuming that every blood-cancer patient needs treatment abroad.

Q2 · How Much Does Leukemia, Lymphoma and Blood Cancer Treatment Cost in India for Kenyan Patients?

Blood-cancer treatment costs vary significantly because one patient may require several cycles of chemotherapy while another may require a stem-cell transplant or cellular therapy.

For planning purposes, this guide uses:

These are approximate planning exchange rates only. Actual exchange rates may vary. Current 2026 Indian planning information indicates that conventional blood-cancer treatment can range broadly depending on the diagnosis and treatment protocol, while stem-cell transplantation and CAR-T therapy are substantially more expensive.

*Potential savings are planning estimates, not guaranteed savings. They depend on the exact diagnosis, treatment protocol, medicines, number of cycles, donor requirements, hospital stay, complications and hospital pricing.

For example, current Indian 2026 sources place autologous transplantation around ₹12–20 lakh and allogeneic transplantation around ₹20–35 lakh in some planning ranges, while CAR-T can be approximately ₹30–60 lakh depending on the therapy and case.

Some published Indian estimates are wider because transplant costs can vary considerably according to donor type, complications and length of admission.

Important: A final quotation should always be obtained from the treating hospital after review of the patient's medical records.

Q3 · Which Indian Cities Can Kenyan Patients Consider?

City Major Medical Facilities / Oncology Ecosystem

For highly complex blood cancers, patients should specifically confirm that the selected hospital has the required hematology, hemato-oncology, bone-marrow transplant or cellular-therapy service rather than selecting a hospital solely by city.

Q4 · Which Hospitals in India Can Kenyan Patients Consider?

The following is the established hospital list used in the Kenya master format.

Important: This is the approved hospital list for the Kenya master format. It should not be interpreted as meaning that every hospital listed provides every blood-cancer treatment. For leukemia, lymphoma, transplantation or CAR-T therapy, patients should specifically confirm the availability of the required hematology/BMT/cellular-therapy programme before travelling.

Q5 · What Types of Leukemia, Lymphoma and Blood Cancer Treatments Are Available?

Blood cancers include several different diseases, and treatment varies considerably between them.

Leukemia

Common categories include:

• Acute lymphoblastic leukemia (ALL)
• Acute myeloid leukemia (AML)
• Chronic myeloid leukemia (CML)
• Chronic lymphocytic leukemia (CLL)

Treatment may include chemotherapy, targeted therapy, immunotherapy and stem-cell transplantation depending on the disease subtype and risk.

Lymphoma

Major categories include:

• Hodgkin lymphoma
• Non-Hodgkin lymphoma

Treatment may involve chemotherapy, antibody-based treatment, targeted therapy, immunotherapy, radiotherapy, stem-cell transplantation or cellular therapy for selected patients.

Other Blood Cancers

Other hematological malignancies may include:

• Multiple myeloma
• Myelodysplastic syndromes
• Myeloproliferative neoplasms
• Other bone-marrow and blood-forming disorders

Major Treatment Approaches

1. Chemotherapy

Uses anti-cancer medicines to destroy or control abnormal cells.

2. Targeted Therapy

Targets particular molecular or cellular characteristics of the disease.

3. Immunotherapy

Uses medicines that help the immune system recognise or attack cancer cells in selected diseases.

4. Radiotherapy

May be used for selected lymphoma or other situations.

5. Stem-Cell/Bone-Marrow Transplantation

May be used for selected leukemia, lymphoma, myeloma and other hematological conditions.

6. CAR-T / Cellular Therapy

Available for selected blood cancers, particularly certain relapsed or refractory diseases, subject to eligibility and centre-specific availability. Specialised Indian centres provide CAR-T and hematopoietic stem-cell transplantation for selected adult and paediatric cancers.

Q6 · What Are the Benefits of Seeking Specialised Blood-Cancer Treatment in India?

Potential benefits include

• Access to specialised hematology teams
• Detailed diagnostic evaluation
• Advanced pathology and molecular testing
• Multidisciplinary treatment planning
• Chemotherapy and targeted treatment
• Stem-cell transplantation at specialised centres
• Selected cellular and CAR-T therapies
• Adult and paediatric hematology programmes
• Management of relapsed or refractory disease
• Supportive care during intensive treatment
• Potentially lower treatment costs compared with some international private-care pathways

However, treatment outcomes depend on the patient's disease biology, treatment response, overall health and many other clinical factors. Cost alone should not be used to select a treatment centre.

Q7 · Who Is Suitable for Leukemia, Lymphoma or Blood-Cancer Treatment in India?

Patients may be referred to India for

• New blood-cancer diagnosis
• Second opinion
• Confirmation of an unclear diagnosis
• Complex leukemia treatment
• Lymphoma treatment
• Relapsed or refractory disease
• Targeted treatment
• Immunotherapy
• Stem-cell transplantation
• CAR-T evaluation
• Paediatric blood-cancer treatment
• Long-term hematology management

Suitability for transplantation or cellular therapy depends on factors including

• Exact diagnosis
• Disease stage/status
• Genetic and molecular findings
• Response to previous treatment
• Age
• General health
• Kidney and liver function
• Infection status
• Previous therapies
• Donor availability, where applicable

The treating hematologist must determine whether a patient is suitable for a particular treatment.

Q8 · What Medical Documents Should Kenyan Patients Send Before Travelling?

A complete medical file is particularly important in blood-cancer cases.

Patients should provide

• Complete blood count (CBC)
• Peripheral blood smear
• Bone-marrow aspiration report
• Bone-marrow biopsy report
• Flow cytometry report
• Histopathology report
• Immunohistochemistry report where applicable
• Cytogenetic/karyotype results
• Molecular/genetic reports
• PET-CT/CT/MRI reports where applicable
• Previous chemotherapy records
• Previous radiotherapy records
• Previous transplant records
• Previous treatment-response reports
• Current medication list
• Blood-transfusion history
• Infection-screening reports
• Kidney and liver-function tests
• Previous discharge summaries
• Treating doctor's referral letter

For lymphoma, pathology slides or tissue blocks may also be requested for specialist pathology review.

For transplant evaluation, additional donor-related investigations may be required.

Q9 · How Does Leukemia, Lymphoma and Blood- Cancer Treatment Work in India?

The treatment pathway generally follows several stages.

Step 1 – Medical Record Review

The Indian hematology team reviews the patient's diagnosis, pathology, laboratory reports and previous treatment.

Step 2 – Diagnostic Confirmation

Additional blood tests, bone-marrow testing, flow cytometry, pathology review or molecular testing may be recommended.

Step 3 – Disease Classification

The exact leukemia, lymphoma or other blood-cancer subtype is identified.

Step 4 – Risk and Disease Assessment

The medical team assesses disease characteristics, molecular findings and response to previous treatment.

Step 5 – Treatment Planning

The team determines whether chemotherapy, targeted therapy, immunotherapy, radiotherapy, transplantation or another approach is appropriate.

Step 6 – Treatment

Treatment may involve outpatient/day-care therapy or hospital admission depending on the protocol.

Step 7 – Response Assessment

Blood tests, bone-marrow examinations, molecular tests or imaging may be used to assess response.

Step 8 – Consolidation or Further Treatment

Depending on the disease, treatment may continue with additional cycles, maintenance treatment, transplantation or another therapy.

Specialised centres may provide chemotherapy, transplantation and cellular therapy within the same hematology programme.

Q10 · What Are the Alternatives to Blood-Cancer Chemotherapy?

Chemotherapy is only one component of blood-cancer treatment.

Depending on the diagnosis, alternatives or complementary approaches may include

1. Targeted Therapy

May be used when the cancer has a specific molecular or cellular target.

2. Immunotherapy

May be appropriate for selected leukemia and lymphoma patients.

3. Radiation Therapy

May be used in selected lymphoma cases or for specific disease sites.

4. Stem-Cell Transplantation

May be recommended for selected patients when disease characteristics and treatment response make transplantation appropriate.

5. CAR-T / Cellular Therapy

May be considered for selected eligible patients with certain relapsed or refractory blood cancers.

6. Maintenance Therapy

Some blood cancers may require longer-term maintenance treatment after initial therapy.

7. Supportive Care

Blood transfusions, infection management, nutritional support and other supportive measures may be an important part of treatment.

8. Clinical Trials

Selected patients may be considered for clinical trials where an appropriate study is available.

The correct treatment should be based on the exact blood-cancer diagnosis and disease biology rather than choosing a treatment simply because it is available.

Q11 · What Should Kenyan Patients Ask Before Accepting a Blood-Cancer Treatment Quotation?

Patients should ask

• What is the exact blood-cancer diagnosis?
• What subtype is it?
• Has the pathology been independently reviewed?
• Is bone-marrow testing required?
• Is flow cytometry required?
• Are cytogenetic or molecular tests required?
• What treatment protocol is recommended?
• How many chemotherapy cycles are expected?
• Is targeted therapy required?
• Is immunotherapy required?
• Is transplantation being considered?
• If transplantation is required, is it autologous or allogeneic?
• Is donor testing included?
• Is CAR-T/cellular therapy appropriate?
• Which medicines are included in the quotation?
• Are blood and platelet transfusions included?
• Are ICU charges included?
• What complications could increase the cost?
• How long is hospital admission expected to be?
• How long should the patient remain in India?
• Can any part of treatment continue in Kenya?
• What follow-up will be required after returning to Kenya?

For complex cases, patients should request a written multidisciplinary treatment plan and itemised quotation rather than relying only on a verbal estimate.

Q12 · How Long Should Kenyan Patients Stay in India?

The duration depends heavily on the treatment plan.

1. Diagnostic Evaluation

Approximately 3–7 days may be required for consultation, pathology review, laboratory investigations and treatment planning.

2. Chemotherapy

Some chemotherapy may be administered through day-care services, while intensive protocols may require hospital admission.

Multiple cycles may require repeated visits over several months.

3. Intensive Leukemia Treatment

Patients receiving intensive leukemia treatment may need prolonged hospitalisation depending on blood counts, infections, treatment response and complications.

4. Stem-Cell Transplantation

Transplantation generally requires a considerably longer treatment journey involving:

• Pre-transplant evaluation
• Donor evaluation where applicable
• Conditioning treatment
• Stem-cell infusion
• Blood-count recovery
• Infection monitoring
• Management of possible complications
• Post-transplant follow-up

Published Indian planning estimates also show that transplant costs and timelines vary significantly according to transplant type, donor and complications.

CAR-T / Cellular Therapy

Cellular therapy requires specialist evaluation, preparation, treatment and close monitoring. The patient should not assume that this can be completed during a short medical-tourism visit. Before booking flights, families should ask:

• How many days are required for diagnosis?
• Can treatment start immediately?
• How many treatment cycles are required?
• Is admission required?
• Can chemotherapy continue in Kenya?
• Is transplantation required?
• How long should the patient remain near the hospital?
• When is it medically safe to fly?

Q13 · What Is Recovery Like After Blood-Cancer Treatment?

Recovery varies significantly according to the disease and treatment.

During Chemotherapy

Patients may experience:

• Fatigue
• Nausea
• Appetite changes
• Low blood counts
• Increased infection risk
• Hair loss with certain regimens
• Weakness
• Need for blood or platelet transfusions

The severity varies according to the medicines and individual patient.

After Stem-Cell Transplantation

Patients require close monitoring for:

• Blood-count recovery
• Infection
• Medication effects
• Nutritional problems
• Transplant-related complications
• Graft-versus-host disease after certain allogeneic transplants

Recovery can continue for months after transplantation.

After Other Blood-Cancer Treatments

Patients may require:

• Nutritional support
• Infection monitoring
• Regular blood tests
• Bone-marrow monitoring
• Molecular monitoring where applicable
• Imaging for selected lymphoma patients
• Medication monitoring
• Long-term surveillance

Patients should receive written instructions about symptoms requiring urgent medical attention before leaving India.

Q14 · How Can Blood-Cancer Follow-Up Be Managed After Returning to Kenya?

Blood-cancer care often continues for months or years after the initial treatment.

Before returning to Kenya, patients should obtain

• Final diagnosis
• Complete pathology report
• Bone-marrow report
• Flow cytometry report
• Molecular/genetic reports
• Complete chemotherapy summary
• Transplant report, if applicable
• Treatment-response reports
• Medication list
• Follow-up schedule
• Recommended blood-test schedule
• Recommended imaging schedule
• Bone-marrow monitoring schedule where applicable
• Warning signs requiring urgent medical review

The Indian hematologist can coordinate with the patient's Kenyan hematologist where appropriate.

This can allow

• Local blood testing
• Medication monitoring
• Continued treatment where medically suitable
• Follow-up imaging
• Long-term disease surveillance
• Management of treatment-related complications

The patient should return to Kenya with a complete written treatment summary rather than relying on memory or verbal instructions.

Q15 · Should a Kenyan Patient Travel to India for Leukemia, Lymphoma and Blood Cancer Treatment?

India can be considered by Kenyan patients seeking

• A second hematology opinion
• Confirmation of a difficult diagnosis
• Complex leukemia treatment
• Specialised lymphoma treatment
• Targeted therapy
• Immunotherapy
• Stem-cell transplantation
• Selected cellular/CAR-T therapy
• Treatment of relapsed or refractory disease
• Paediatric blood-cancer treatment

However, overseas treatment is not automatically required for every blood-cancer patient.

A Kenyan patient considering India should compare

• Exact blood-cancer diagnosis
• Disease subtype
• Molecular and genetic findings
• Recommended treatment
• Specialist experience
• Availability of required medicines
• Transplant requirements
• Donor availability
• Cellular-therapy eligibility
• Total treatment cost
• Expected duration of treatment
• Hospital stay
• Travel requirements
• Follow-up arrangements in Kenya

For many patients, an appropriate first step is to obtain an Indian hematology/oncology second opinion based on the complete medical records before travelling.

This can help determine whether the patient requires chemotherapy, targeted therapy, immunotherapy, transplantation, cellular therapy or another treatment approach.

Kenyan Patient Pre-Travel Checklist

Medical Records

• Complete blood count and blood-test reports
• Peripheral blood smear
• Bone-marrow aspiration report
• Bone-marrow biopsy report
• Flow cytometry report
• Histopathology report
• Immunohistochemistry report where applicable
• Cytogenetic/karyotype reports
• Molecular/genetic reports
• CT/MRI/PET-CT reports where applicable
• Previous chemotherapy records
• Previous radiotherapy records
• Previous transplant records
• Treatment-response reports
• Current medication list
• Previous discharge summaries

Treatment Planning

• Confirm exact blood-cancer diagnosis
• Confirm disease subtype
• Confirm molecular/genetic findings
• Obtain specialist hematology opinion
• Ask whether additional diagnostic testing is required
• Ask about chemotherapy
• Ask about targeted therapy
• Ask about immunotherapy
• Ask whether transplantation is required
• Ask whether donor testing is required
• Ask about CAR-T/cellular therapy where applicable
• Obtain written treatment plan

Hospital and Cost

• Confirm hematology/hemato-oncology specialists
• Confirm transplant facilities where required
• Confirm cellular-therapy availability where required
• Obtain written quotation
• Confirm chemotherapy charges
• Confirm medicine costs
• Confirm diagnostic and molecular-testing charges
• Confirm blood and platelet transfusion charges
• Confirm transplant-related charges
• Ask about ICU charges
• Ask about possible complications and additional costs

Travel

• Valid passport
• Appropriate Indian medical-visa documentation
• Printed and digital medical records
• Accommodation arrangements
• Flexible return-flight arrangements
• Travel companion where appropriate
• Medical insurance information where available

Follow-Up

• Final diagnosis
• Complete pathology report
• Bone-marrow report
• Flow cytometry report
• Molecular/genetic reports
• Chemotherapy summary
• Transplant report where applicable
• Medication schedule
• Blood-test schedule
• Imaging schedule where applicable
• Follow-up appointment plan
• Kenyan hematologist/follow-up arrangements
• Emergency warning signs understood

Final Note

Leukemia, Lymphoma and Blood Cancer Treatments in India for Kenyan Patients can include specialised diagnosis, chemotherapy, targeted therapy, immunotherapy, radiation therapy, stem-cell/bone-marrow transplantation, CAR-T/cellular therapy and supportive cancer care. The most important factor is not simply the treatment location or quoted price. Treatment should be based on the correct diagnosis, accurate disease classification, pathology, molecular information, treatment response and a clear multidisciplinary treatment plan. For Kenyan patients considering treatment in India, sending the complete medical records for specialist review before travelling can help determine the appropriate treatment pathway, expected duration, hospital requirements and approximate cost. India has specialised hematology and oncology centres offering chemotherapy, stem-cell transplantation and selected cellular therapies, but the appropriate treatment and hospital should always be selected according to the patient's individual medical requirements. Your health journey deserves informed planning, specialist evaluation and coordinated care — from Kenya to India and back home.

Page Summary

This page answers 15 frequently asked questions about leukemia, lymphoma and blood cancer treatments in India for Kenyan patients. It covers why patients travel for treatment, an indicative Kenya-versus-India cost comparison, the Indian cities and hospitals to consider, the treatment and surgical options available, how to obtain a quotation remotely, second opinions, advanced options, recovery, unexpected costs, combining treatments, medical visa and travel planning, length of stay, follow-up after returning to Kenya, and a complete pre-travel checklist.